The increasing genetic diversity of HIV-1 in the UK, 2002-2010. AIDS. 28:773-80.. 2014.
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect. 68:77-84.. 2014.
Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of Circulating Recombinant Form (CRF) 50_A1D. PLoS One. 9:e83337.. 2014.
Protease mutations emergining on darunavir in protease inhibitor-naive and experienced patients in the UK. International Congress of Drug Therapy in HIV Infection, November 2014.. 2014.
HIV Virulence has not increased in the UK subtype B epidemic. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.. 2014.
Sustained Spread of HIV-1 Drug Resistance in Treatment-Naïve Patients in the United Kingdom. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.. 2014.
Transmission and persistence of antiretroviral resistance amongst drug naïve HIV positive individuals in the United Kingdom. International Workshop on Antiviral Drug Resistance, June 2014.. 2014.
National audit of baseline HIV resistance testing among newly-diagnosed adults. Third Joint Conference of BHIVA and BASHH, 1-14 April 2014.. 2014.
Detection of NNRTI resistance mutations after interrupting NNRTI-based regimens. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.. 2014.
Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 208:1459-63.. 2013.
Automated analysis of phylogenetic clusters. BMC Bioinformatics. 14:317.. 2013.
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother. 68:2339-43.. 2013.
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med. 14:571-7.. 2013.
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 27:2245-53.. 2013.
Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 68:1220-36.. 2013.
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.. 2013.
HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Clin Infect Dis. 56:162-3.. 2013.
Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Antivir Ther. 18:213-9.. 2013.
Rapid Increase in the Frequency of Wild Type HIV-1 Drug Resistance Reports among ART-experienced Patients: UK. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.. 2013.
Viral Genotype in Subtype C Significantly Influences Plasma Viral Load. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.. 2013.